FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766024409> ?p ?o ?g. }

• W2766024409 endingPage "64" @default.
• W2766024409 startingPage "57" @default.
• W2766024409 abstract "Aims To assess long-term outcomes and resource use of 4D Brachytherapy, a one-stage real-time implant for the treatment of prostate cancer that uses stranded and loose iodine-125 seeds, and to compare with the conventional two-stage (2S) technique. Materials and methods Prospectively collected data of men who underwent 2S and 4D low dose rate brachytherapy in a single institution were analysed. Survival estimates were analysed using the Kaplan–Meier method and Log-rank test. Treatment failure rates were further compared by Cox proportional hazards (Coxph) regression or by a surrogate prostate-specific antigen value cut-off of 0.4 ng/ml 48 months post-implant. Treatment toxicity outcomes were also evaluated. Comparative costs were based on published English National Health Service data. Results We compared outcomes of 690 men treated with 2S and 1031 men with 4D brachytherapy. Median follow-up times were 10.4 and 5.2 years (P < 0.001) for 2S and 4D cases, respectively. Day 0 post-implant dosimetry was improved in 4D brachytherapy patients. Five years post-implant ≥98% of cases were alive and ≥95% were free from disease relapse irrespective of technique. Coxph regression showed the risk of relapse after 4D brachytherapy was similar to the 2S technique (hazard ratio 0.67, 95% confidence interval 0.44–1.03, P = 0.065). Forty-eight months post-implant there was a significantly greater proportion of 4D brachytherapy cases with a prostate-specific antigen below 0.4 ng/ml relative to the 2S technique. Urinary and bowel symptom scores showed reduced toxicity after 4D implants and potency conservation was similar to the 2S technique. The reduction in time and resource use decreased the cost of 4D brachytherapy by 40% compared with the 2S technique. Conclusion Two-stage and 4D brachytherapy are both highly effective for the control of localised prostate cancer. However, relative to the 2S technique, the 4D technique was associated with improved dosimetry, reduced treatment-related toxicity and reduced cost. Further follow-up will assess disease control superiority of 4D brachytherapy beyond 5 years post-implant." @default.
• W2766024409 created "2017-11-10" @default.
• W2766024409 creator A5003056494 @default.
• W2766024409 creator A5017537354 @default.
• W2766024409 creator A5026151822 @default.
• W2766024409 creator A5056626622 @default.
• W2766024409 creator A5068373079 @default.
• W2766024409 creator A5075187117 @default.
• W2766024409 creator A5081228031 @default.
• W2766024409 creator A5086077558 @default.
• W2766024409 date "2018-01-01" @default.
• W2766024409 modified "2023-09-25" @default.
• W2766024409 title "Comparative Analysis of Clinical Outcomes and Procedural Costs between the Conventional Two-stage Technique and 4D Brachytherapy for Early Prostate Cancer" @default.
• W2766024409 cites W1571792083 @default.
• W2766024409 cites W1608287211 @default.
• W2766024409 cites W1965536955 @default.
• W2766024409 cites W1986061859 @default.
• W2766024409 cites W2024550742 @default.
• W2766024409 cites W2025824469 @default.
• W2766024409 cites W2066800897 @default.
• W2766024409 cites W2095740768 @default.
• W2766024409 cites W2097748024 @default.
• W2766024409 cites W2102251996 @default.
• W2766024409 cites W2123420657 @default.
• W2766024409 cites W2153386196 @default.
• W2766024409 cites W2156183248 @default.
• W2766024409 cites W2156844161 @default.
• W2766024409 cites W2170291645 @default.
• W2766024409 cites W4294344900 @default.
• W2766024409 doi "https://doi.org/10.1016/j.clon.2017.09.006" @default.
• W2766024409 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29054374" @default.
• W2766024409 hasPublicationYear "2018" @default.
• W2766024409 type Work @default.
• W2766024409 sameAs 2766024409 @default.
• W2766024409 citedByCount "7" @default.
• W2766024409 countsByYear W27660244092018 @default.
• W2766024409 countsByYear W27660244092019 @default.
• W2766024409 countsByYear W27660244092021 @default.
• W2766024409 crossrefType "journal-article" @default.
• W2766024409 hasAuthorship W2766024409A5003056494 @default.
• W2766024409 hasAuthorship W2766024409A5017537354 @default.
• W2766024409 hasAuthorship W2766024409A5026151822 @default.
• W2766024409 hasAuthorship W2766024409A5056626622 @default.
• W2766024409 hasAuthorship W2766024409A5068373079 @default.
• W2766024409 hasAuthorship W2766024409A5075187117 @default.
• W2766024409 hasAuthorship W2766024409A5081228031 @default.
• W2766024409 hasAuthorship W2766024409A5086077558 @default.
• W2766024409 hasConcept C121608353 @default.
• W2766024409 hasConcept C126322002 @default.
• W2766024409 hasConcept C126894567 @default.
• W2766024409 hasConcept C141071460 @default.
• W2766024409 hasConcept C146357865 @default.
• W2766024409 hasConcept C151730666 @default.
• W2766024409 hasConcept C207103383 @default.
• W2766024409 hasConcept C2776235491 @default.
• W2766024409 hasConcept C2777416452 @default.
• W2766024409 hasConcept C2778648096 @default.
• W2766024409 hasConcept C2780192828 @default.
• W2766024409 hasConcept C2781406297 @default.
• W2766024409 hasConcept C2781411149 @default.
• W2766024409 hasConcept C2989005 @default.
• W2766024409 hasConcept C44249647 @default.
• W2766024409 hasConcept C50382708 @default.
• W2766024409 hasConcept C509974204 @default.
• W2766024409 hasConcept C71924100 @default.
• W2766024409 hasConcept C86803240 @default.
• W2766024409 hasConceptScore W2766024409C121608353 @default.
• W2766024409 hasConceptScore W2766024409C126322002 @default.
• W2766024409 hasConceptScore W2766024409C126894567 @default.
• W2766024409 hasConceptScore W2766024409C141071460 @default.
• W2766024409 hasConceptScore W2766024409C146357865 @default.
• W2766024409 hasConceptScore W2766024409C151730666 @default.
• W2766024409 hasConceptScore W2766024409C207103383 @default.
• W2766024409 hasConceptScore W2766024409C2776235491 @default.
• W2766024409 hasConceptScore W2766024409C2777416452 @default.
• W2766024409 hasConceptScore W2766024409C2778648096 @default.
• W2766024409 hasConceptScore W2766024409C2780192828 @default.
• W2766024409 hasConceptScore W2766024409C2781406297 @default.
• W2766024409 hasConceptScore W2766024409C2781411149 @default.
• W2766024409 hasConceptScore W2766024409C2989005 @default.
• W2766024409 hasConceptScore W2766024409C44249647 @default.
• W2766024409 hasConceptScore W2766024409C50382708 @default.
• W2766024409 hasConceptScore W2766024409C509974204 @default.
• W2766024409 hasConceptScore W2766024409C71924100 @default.
• W2766024409 hasConceptScore W2766024409C86803240 @default.
• W2766024409 hasIssue "1" @default.
• W2766024409 hasLocation W27660244091 @default.
• W2766024409 hasLocation W27660244092 @default.
• W2766024409 hasOpenAccess W2766024409 @default.
• W2766024409 hasPrimaryLocation W27660244091 @default.
• W2766024409 hasRelatedWork W1992657261 @default.
• W2766024409 hasRelatedWork W1995422080 @default.
• W2766024409 hasRelatedWork W2038565121 @default.
• W2766024409 hasRelatedWork W2148869351 @default.
• W2766024409 hasRelatedWork W2165532162 @default.
• W2766024409 hasRelatedWork W2373651588 @default.
• W2766024409 hasRelatedWork W2897445903 @default.
• W2766024409 hasRelatedWork W3129209394 @default.

• next